Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | XDH | P47989 | 3/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672641 | 1.00 | CTSK (0.41) | CTSKXDHAAK1MEN1KMT2A | |
| SCHEMBL4162120 | 1.00 | CTSK (0.41) | CTSKXDHAAK1MEN1KMT2A | |
| SCHEMBL31226247 | 0.85 | KMT2A (0.44) | CTSKAAK1MEN1KMT2A | |
| SCHEMBL8216304 | 0.81 | ROCK2 (0.53) | CTSKAAK1ABCB1CYP17A1MAPK1 | |
| SCHEMBL9930795 | 0.81 | ROCK2 (0.53) | CTSKAAK1ABCB1CYP17A1MAPK1 | |
| SCHEMBL9930794 | 0.81 | ROCK2 (0.53) | CTSKAAK1ABCB1CYP17A1MAPK1 | |
| SCHEMBL1754171 | 0.80 | SMN1; SMN2 (0.53) | CTSKAAK1MEN1KMT2ALMNA | |
| SCHEMBL256792 | 0.80 | SMN1; SMN2 (0.53) | CTSKAAK1MEN1KMT2ALMNA | |
| SCHEMBL167410 | 0.80 | SMN1; SMN2 (0.53) | CTSKAAK1MEN1KMT2ALMNA | |
| SCHEMBL3378929 | 0.80 | CYP17A1 (0.56) | MEN1KMT2ACYP17A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | CTSK 4717/4885XDH 291/4885AAK1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.